[1]王金志,陶新曹,谢万木,等.球囊肺动脉成形术治疗近端慢性血栓栓塞性肺动脉高压的安全性和有效性[J].介入放射学杂志,2023,32(08):746-749.
WANG Jinzhi,TAO Xincao,XIE Wanmu,et al.The safety and efficacy of balloon pulmonary angioplasty in the treatment of proximal-type chronic thromboembolic pulmonary hypertension[J].journal interventional radiology,2023,32(08):746-749.
点击复制
球囊肺动脉成形术治疗近端慢性血栓栓塞性肺动脉高压的安全性和有效性(
)
《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]
- 卷:
-
32
- 期数:
-
2023年08
- 页码:
-
746-749
- 栏目:
-
血管介入
- 出版日期:
-
2023-08-29
文章信息/Info
- Title:
-
The safety and efficacy of balloon pulmonary angioplasty in the treatment of proximal-type chronic thromboembolic pulmonary hypertension
- 作者:
-
王金志; 陶新曹; 谢万木; 张 帅; 张 竹; 傅志辉; 李宜珊; 赵蕴伟; 黄 强; 翟振国
-
- Author(s):
-
WANG Jinzhi; TAO Xincao; XIE Wanmu; ZHANG Shuai; ZHANG Zhu; FU Zhihui; LI Yishan; ZHAO Yunwei; HUANG Qiang; ZHAI Zhenguo.
-
Graduate School of Jiamusi University, Jiamusi City, Heilongjiang Province154007, China
-
- 关键词:
-
【关键词】 慢性血栓栓塞性肺动脉高压; 平均肺动脉压; 肺动脉内膜剥脱术; 球囊肺动脉成形术
- 文献标志码:
-
A
- 摘要:
-
【摘要】 目的 评估球囊肺动脉成形术(BPA)治疗近端慢性血栓栓塞性肺动脉高压(CTEPH)的安全性和有效性。方法 纳入2016年12月至2022年1月在中日友好医院呼吸中心住院的CTEPH患者46例,均接受BPA。比较术前与术后患者的WHO心功能分级、6 min步行距离(6MWD)、血N-末端脑钠肽前体(NT- proBNP)水平、混合静脉血氧饱和度(SvO2)、平均肺动脉压(mPAP)、心指数和肺血管阻力(PVR)。结果 46例行BPA治疗的CTEPH患者中,男性17例,女性29例,年龄(57.0±12.7)岁。行126次BPA,共治疗545支病变血管,平均每次治疗血管数2.7支。术前患者的WHO心功能Ⅰ、Ⅱ、Ⅲ、Ⅳ级分别为1例(2.2%)、24例(52.1%)、17例(37.0%)、4例(8.7%),6MWD为(359.6±112.3) m,SvO2为(64.5±8.8)%;术后WHO心功能Ⅰ、Ⅱ、Ⅲ、Ⅳ级分别为6例(13.0%)、31例(67.4%)、13例(28.3%)、2例(4.3%),6MWD为(436.7±97.9) m,SvO2为(66.4±5.5)%(均P<0.05)。术后血浆NT- proBNP、mPAP、PVR、心指数、右心房压力均低于术前,分别为262(145,746) ng/L比955(242,2781) ng/L、(29.2±9.9) mmHg比(39.4±9.5) mmHg、(6.6±2.7)WU比(12.1±6.2)WU、(1.1±0.7) L/(min?m2)比(1.7±0.8) L/(min?m2)、(3.7±3.0) mmHg比(5.1±4.4) mmHg(均P<0.05)。咯血共5例次,再灌注肺水肿1例次,无其他并发症发生。结论 BPA是治疗近端CTEPH患者安全、有效的方法。
参考文献/References:
[1] 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组,等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021, 101:11- 51.
[2] Riedel M,Stanek V,Widimsky J,et al. Longterm follow- up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data[J]. Chest, 1982, 81:151- 158.
[3] Ito R, Yamashita J, Sasaki Y, et al. Efficacy and safety of balloon pulmonary angioplasty for residual pulmonary hypertension after pulmonary endarterectomy[J]. Int J Cardiol, 2021, 334:105- 109.
[4] Delcroix M, Lang I, Pepke- Zaba J, et al. Long- term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry[J]. Circulation,2016,133:859- 871.
[5] Humbert M,Kovacs G,Hoeper MM,et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J,2023,61:2200879.
[6] Jiang X, Peng FH, Liu QQ, et al. Optical coherence tomography for hypertensive pulmonary vasculature[J]. Int J Cardiol, 2016,222:494- 498.
[7] Jais X, Brenot P, Bouvaist H, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension(RACE): a multicentre, phase 3, open- label, randomised controlled trial and ancillary follow- up study[J]. Lancet Respir Med,2022,10:961- 971.
[8] Kawakami T, Ogawa A, Miyaji K, et al. Novel angiographic classification of each vascular lesion in chronic thromboe- mbolic pulmonary hypertension based on selective angiogram and results of balloon pulmonary angioplasty[J]. Circ Cardiovasc Interv, 2016, 9:e003318.
[9] Hsieh WC, Jansa P, Huang WC,et al. Residual pulmonary hypertension after pulmonary endarterectomy: a meta- analysis[J]. J Thorac Cardiovasc Surg,2018,156:1275- 1287.
[10] Alegria S,Cale R,Ferreira F,et al. Optical coherence tomography- guided balloon pulmonary angioplasty of a web lesion[J]. Rev Port Cardiol (Engl Ed),2019 ,38:227- 228.
[11] Shimokawahara H, Ogawa A, Matsubara H. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: advances in patient and lesion selection[J]. Curr Opin Pulm Med, 2021, 27:303- 310.
[12] Hug KP, Gerry CJ, Cannon J, et al. Serial right heart catheter assessment between balloon pulmonary angioplasty sessions identify procedural factors that influence response to treatment[J]. J Heart Lung Transplant, 2021, 40:1223- 1234.
[13] Araszkiewicz A,Darocha S,Pietrasik A,et al. Balloon pulmonary angioplasty for the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomy[J]. Int J Cardiol,2019, 278:232- 237.
[14] Cannon JE, Su L, Kiely DG, et al. Dynamic risk stratification of patient long- term outcome after pulmonary endarterectomy: results from the United Kingdom National Cohort[J]. Circulation, 2016, 133:1761- 1771.
[15] Tanabe N, Kawakami T, Satoh T, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a systematic review[J]. Respir Investig, 2018, 56:332- 341.
[16] Wiedenroth CB,Deissner H,Adameit MSD,et al. Complications of balloon pulmonary angioplasty for inoperable chronic throm-boembolic pulmonary hypertension: Impact on the outcome[J]. J Heart Lung Transplant,2022,41:1086- 1094.
[17] Darocha S,Roik M,Kopec G,et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: a multicentre registry[J]. EuroIntervention,2022,17:1104- 1111.
[18] Kim NH,Delcroix M,Jais X, et al. Chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2019, 53:1801915.
备注/Memo
- 备注/Memo:
-
(收稿日期:2022- 11- 19)
(本文编辑:新 宇)
更新日期/Last Update:
2023-08-29